PR96082

MONTREAL, May 19, 2022 /PRNewswire=KYODO JBN/ --

  -- This acquisition solidifies CellCarta's leadership position in

     proteomics services with a unique combination of validated set of

     reagents and multiplex assays, including pathway specific

     off-the-shelf panels, allowing for clinical protein quantification

     covering a comprehensive range of immuno-oncology targets.    

CellCarta, a leading global provider of precision medicine laboratory services,

announced today the acquisition of the commercial rights to the antibody panels

and assays from Precision Assays, a leader in next-generation targeted

proteomics testing solutions. A spin-off from Fred Hutchinson Cancer Center

("Fred Hutch"), Precision Assays develops and deploys high-end multiplex

quantitative immuno-MRM mass spectrophotometry-based assays for its

pharmaceutical and biotech industry clients.

Logo -

https://mma.prnewswire.com/media/1821170/CellCarta_CellCarta_expands_it_proteomics_portfolio_with_the_acq.jpg

Logo -

https://mma.prnewswire.com/media/1821171/CellCarta_CellCarta_expands_it_proteomics_portfolio_with_the_acq.jpg

The acquisition from Precision Assays of its large spectrum of targeted mass

spectrometry assays characterized according to the National Cancer Institute's

Clinical Proteomic Tumor Analysis Consortium (CPTAC) Tier 2 guidelines greatly

expands CellCarta's capabilities in off-the-shelf multiplex protein

quantification offerings ready for deployment in immuno-oncology clinical and

pre-clinical studies. "Precision Assays' large portfolio of robust assays

characterized according to CPTAC guidelines and its established proof of

concept data will enable CellCarta to confidently support its clients'

exploratory studies and therapeutic development strategies, offering them key

solutions to address important clinical challenges and move their

immuno-oncology programs forward. Given CellCarta's expertise in protein

quantitation, these immuno-MRM panels can further be validated to support

secondary and primary clinical endpoints" said Lorella Di Donato, Chief

Operating Officer of CellCarta, Immunology and Proteomics Divisions. Acquiring

Precision Assays' portfolio of validated assays strengthens CellCarta's growth

strategy to become the leading provider of precision medicine services and will

allow the organization to extend proteomics services from discovery to clinical

settings.

Based on technology licensed from Fred Hutch, Precision Assays' platform is

uniquely positioned to fully capture the unique advantages of multiplex protein

quantification using targeted mass spectrometry. Founder Dr. Amanda Paulovich,

a professor in the Clinical Research Division at Fred Hutch who holds the Aven

Foundation Endowed Chair, is an internationally recognized pioneer in targeted

mass spectrometry and a clinically trained oncologist. Dr. Paulovich has set

best-in-class standards to support precision medicine studies in

cancer-specific protein expression analysis in a variety of matrices from FFPE

cancer tissue biopsies to clinical serum-based samples. Precision Assays is one

of the few CROs to offer large and immuno-oncology relevant multiplex

off-the-shelf panels and is at the forefront of targeted-mass spec

proteomics-based research.

"As a global CRO with expertise in targeted mass spectrometry and specializing

in biomarker testing to support precision medicine, CellCarta is an ideal

partner to deploy and industrialize our platform to support discovery,

translational and clinical research, especially in precision medicine and

immuno-oncology", Paulovich said.

About CellCarta

CellCarta is a leading provider of specialized precision medicine laboratory

services to the biopharmaceutical industry. Leveraging its integrated

analytical platforms in immunology, histopathology, proteomics and genomics, as

well as related specimen collection and logistics services, CellCarta supports

the entire drug development cycle, from discovery to late-stage clinical

trials. The company operates globally with 11 facilities located in Canada,

USA, Belgium, Australia, and China.

For more information: cellcarta.com (

https://c212.net/c/link/?t=0&l=en&o=3541619-1&h=483922780&u=http%3A%2F%2Fwww.cellcarta.com%2F&a=cellcarta.com

)

About Precision Assays

Precision Assays, LLC is a company based on technology licensed from Fred

Hutchinson Cancer Center. The company provides quantitative protein assays to

biotechnology and pharmaceutical partners.

CONTACT : CellCarta, Stephanie Bussières-Marmen, PhD, Manager, Global

Marketing, stephanie.marmen@cellcarta.com

Source - CellCarta